Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection

International Journal of Hematology

Volumn 78, Issue 1, 2003, Pages 62-68

  Hagihara, Masao ^a   Tsuchiya, Takahide ^a   Hyodo, Osamu ^b   Ueda, Yoko ^a   Tazume, Kei ^a   Masui, Aya ^a   Kanemura, Ayako ^a   Yoshiba, Fumiaki ^a   Takashimizu, Shinji ^a   Matzusaki, Shohei ^a   Kato, Shunichi ^a   Hotta, Tomomitsu ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cytotoxic T lymphocytes; Lymphokine activated killer cells; Severe chronic active Epstein Barr virus infection

Indexed keywords

CYTOKINE RECEPTOR; GAMMA INTERFERON; PREDNISOLONE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DNA DETERMINATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS LOAD;

EID: 0042848517     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983242     Document Type: Article

References (31)

1. Kimura H, M Morita, I Tsuge, et al. Vidarabine therapy for severe chronic active Epstein-Barr virus infection. J Pediatr Hematol OncoL 2001;23:294-299.
2. Ishida Y, Yokota Y, Tauchi H, et al. Ganciclovir for chronic active Epstein-Barr virus infection. Lancet. 1993;341:560-561.
3. Kawa-Ha K, Franco E, Doi S, et al. Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. Lancet. 1987;1:154.
4. Sakai Y, Ohga S, Tonegawa Y, ct al. Interferon-alpha therapy for chronic active Epstein-Barr virus infection: potential effect on the development of T-lymphoproliferative disease. J Pediatr Hematol Oncol. 1998;20:342-346.
5. Kawa K. Epstein-Barr virus-associated diseases in humans. Int J Hematol. 2000;71:108-117.
6. Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet. 2000;356:223-224.
7. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280-286.
8. Kuis W, Roord JJ, Zegers BJ, et al. Heterogeneity of immune defects in three children with a chronic active Epstein-Barr virus infection. J Clin Immunol 1985;5:377-385.
9. Kimura H, Tsuge I, Imai S, ct al. Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection. Med Microbiol Immunol (Berl). 1995;184:63.
10. Hagihara M, Tsuchiya T, Ueda Y, et al. Successful in vitro generation of Epstein-Barr virus-specific cytotoxic T lymphocytes from severe chronic active EBV patients. Med Microbiol Immunol (Berl). 2001;189:137-145.
11. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol 1998;9:S129-S13.
12. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92: 1549-1555.
13. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177:339-349.
14. Kimura H, Nagasaka T, Hoshino Y, et al. Severe hepatitis caused by Epstein-Barr virus without infection of hepatocytes. Hum Pathol. 2001;32:757-762.
15. Lee SP, Chan AT, Cheung ST, et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol. 2000;165:573-582.
16. Kuzushima K, Yamamoto M, Kimura H, et al. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol. 1996;103:192-198.
17. Kuzushima K, Hoshino Y, Fujii K, et al. Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry. Blood. 1999;94:3094-3100.
18. Kuzushima K, Kimura H, Hoshino Y, et al. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder. J Infect Dis. 2000;182: 937-940
19. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132-136.
20. Imai S, Sugiura M, Oikawa O, et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. Blood. 1996;87:1446-1457.
21. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15: 405-431.
22. Tan LC, Gudgeon N, Annels NE, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162:1827-1835.
23. Blake N, Lee S, Redchenko I, et al. Human CD8+ T cell responses to EBV EBNAI: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity. 1997;7: 791-802.
24. Munz C, Bickham KL, Subklewe M, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000;191:1649-1660.
25. Wen S, Shimizu N, Yoshiyama H, Mizugaki Y, Shinozaki F, Takada K. Association of Epstein-Barr virus (EBV) with Sjogren's syndrome: differential EBV expression between epithelial cells and lymphocytes in salivary glands. Am J Pathol. 1996;149:1511-1517.
26. Vaughan JH, Nguyen MD, Valbracht JR, Patrick K, Rhodes GH. Epstein-Barr virus-induced autoimmune responses, II: immunoglobulin G autoantibodies to mimicking and nonmimicking epitopes - presence in autoimmune disease. J Clin Invest. 1995;95: 1316-1327.
27. Vaughan JH, Valbracht JR, Nguyen MD, et al. Epstein-Barr virus-induced autoimmune responses, I: immunoglobulin M autoanti-bodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1. J Clin Invest. 1995;95:1306-1315.
28. Kojima K, Nagayama R, Hirama S, et al. Epstein-Barr virus infection resembling autoimmune hepatitis with lactate dehydrogenase and alkaline phosphatase anomaly. J Gastroenterol. 1999;34: 706-712.
29. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356:802-807.
30. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;110:4059-4066.
31. Jones JF, Straus SE. Chronic Epstein-Barr virus infection. Annu Rev Med. 1987;38:195-209.